Effect of hepatectomy combined with postoperative FOLFOX4 for the treatment of hepatocellular carcinoma with MVI: A prospective randomised controlled trail

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035478

Enrollment

Unknown

Registered

2020-08-12

Start date

2020-08-15

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

A:Surgery plus Folfox4

B:Surgery

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20 to 70 years old male or non-pregnant female HCC with MVI patients; 2. Pathologically proved HCC with MVI; 3. Liver function is Child-Pugh A; 4. No apparent abnormality of the heart, lung, and kidney; 5. No HCV, HIV and syphilis infection; 6. Patients should sign the informed consent of this study.

Exclusion criteria

Exclusion criteria: 1. If postoperative liver function is Child C, it cannot tolerate radiotherapy; 2. With evidence of extrahepatic metastasis; 3. Severe gastroesophagealvarices with red sign or with variceal hemorrhage before; 4. Malignant or metastatic tumor in other sites in last 5 years; 5. Patients can not be followed-up regularly; 6. Patients participating in other trials or received other treatment previously.

Design outcomes

Primary

Measure	Time frame
DFS;	—

Countries

China

Contacts

Public ContactCheng Shuqun

Eastern Hepatobiliary Surgical Hospital

chengshuqun163@163.com+86 021-81875251

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026